Oxford Nanopore Technologies has raised £48.4M ($59.2M) in new capital.
The funding comes from new investors and existing shareholders in EMEA, US and Asia, and adds to the £29M of new capital raised in Q4 2019.
Further information on Oxford Nanopore’s fundraising will be made available after full closing.
Oxford Nanopore’s sequencing devices are used in worldwide scientific research, and increasingly in regulated environments such as healthcare and food safety. The technology is being used extensively for epidemiology and research purposes in the current COVID-19 pandemic and the Company has a new category of COVID test, LamPORE, in advanced development.